Trust Co. of Vermont Lowers Stake in Prestige Consumer Healthcare Inc. (NYSE:PBH)

Trust Co. of Vermont cut its stake in shares of Prestige Consumer Healthcare Inc. (NYSE:PBH) by 34.4% in the fourth quarter, according to its most recent disclosure with the SEC. The firm owned 10,326 shares of the company’s stock after selling 5,418 shares during the period. Trust Co. of Vermont’s holdings in Prestige Consumer Healthcare were worth $632,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the stock. GAMMA Investing LLC purchased a new position in shares of Prestige Consumer Healthcare during the 4th quarter worth $25,000. Pacer Advisors Inc. raised its holdings in shares of Prestige Consumer Healthcare by 85.7% in the 4th quarter. Pacer Advisors Inc. now owns 442 shares of the company’s stock valued at $27,000 after purchasing an additional 204 shares in the last quarter. Provence Wealth Management Group acquired a new stake in shares of Prestige Consumer Healthcare during the third quarter worth about $26,000. Principal Securities Inc. purchased a new position in shares of Prestige Consumer Healthcare during the fourth quarter worth approximately $29,000. Finally, ORG Partners LLC acquired a new position in Prestige Consumer Healthcare in the fourth quarter valued at $36,000. 99.95% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several research firms have issued reports on PBH. DA Davidson reiterated a “neutral” rating and issued a $65.00 price objective on shares of Prestige Consumer Healthcare in a research report on Thursday, May 16th. Canaccord Genuity Group reissued a “buy” rating and set a $80.00 price objective on shares of Prestige Consumer Healthcare in a research note on Tuesday, May 21st. Finally, StockNews.com cut shares of Prestige Consumer Healthcare from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, May 21st. Two equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $91.25.

Prestige Consumer Healthcare Stock Performance

Shares of NYSE:PBH traded up $0.02 during trading on Monday, reaching $64.27. 5,204 shares of the company’s stock traded hands, compared to its average volume of 243,097. Prestige Consumer Healthcare Inc. has a 12 month low of $56.25 and a 12 month high of $75.31. The company has a debt-to-equity ratio of 0.68, a current ratio of 3.20 and a quick ratio of 2.02. The stock has a market capitalization of $3.21 billion, a P/E ratio of 15.41, a price-to-earnings-growth ratio of 1.82 and a beta of 0.50. The company has a 50 day moving average of $67.46 and a 200-day moving average of $66.16.

Prestige Consumer Healthcare (NYSE:PBH) last released its earnings results on Tuesday, May 14th. The company reported $1.02 EPS for the quarter, missing the consensus estimate of $1.14 by ($0.12). Prestige Consumer Healthcare had a net margin of 18.60% and a return on equity of 13.48%. The business had revenue of $277.00 million for the quarter, compared to analyst estimates of $287.42 million. During the same period in the prior year, the company earned $1.07 earnings per share. The firm’s revenue for the quarter was down 3.1% on a year-over-year basis. On average, equities analysts expect that Prestige Consumer Healthcare Inc. will post 4.42 EPS for the current year.

Prestige Consumer Healthcare Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.